Abstract: The present invention provides a method for producing a concentrated antibody preparation that includes the steps of: (a) obtaining an initial antibody preparation that is an aqueous solution of antibodies and histidine or acetate buffer at a concentration in the range of from about 2 mM to about 48 mM; and (b) subjecting the antibody preparation to membrane filtration so as to remove water and buffer but not antibodies from the antibody preparation, thereby producing an antibody preparation having a higher concentration of antibodies than the initial antibody preparation. The concentrated antibody preparations produced by the method have lower viscosity and are more stable than those of other formulations. The invention further includes concentrated antibody preparations produced by the method, pharmaceutical compositions made using such preparations, and therapeutic methods in which such pharmaceutical compositions are administered to treat diseases.
Type:
Application
Filed:
June 23, 2003
Publication date:
August 17, 2006
Applicant:
Biogen Idec, Inc.
Inventors:
Tzung-Horng Yang, Michael Bacica, Michael Labarre
Abstract: The present invention relates to Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.
Type:
Grant
Filed:
October 29, 2004
Date of Patent:
August 8, 2006
Assignees:
The Faculty of Medicine of the University of Geneva, Biogen Idec MA Inc.
Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
Type:
Application
Filed:
March 30, 2006
Publication date:
August 3, 2006
Applicant:
Biogen Idec Inc.
Inventors:
Kandasamy Hariharan, Nabil Hanna, Gary Braslawsky, Nuzhat Pathan
Abstract: A cell adhesion inhibitor of the general formula: R3-L-L?-R1 is disclosed. An inhibitor of the present invention interacts with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. Also disclosed are methods for preparing and using such a cell adhesion inhibitor, as well as pharmaceutical compositions containing the same.
Type:
Application
Filed:
February 27, 2006
Publication date:
July 27, 2006
Applicant:
Biogen Idec MA Inc.
Inventors:
Daniel Scott, Wen-Cherng Lee, Russell Petter, Mark Cornebise
Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases.
Type:
Grant
Filed:
June 17, 2002
Date of Patent:
July 11, 2006
Assignee:
Biogen IDEC Inc.
Inventors:
Amelia Black, Nabil Hanna, Eduardo A. Padlan, Roland A. Newman
Abstract: The disclosure provides an expression cassette and a vector comprising the cassette for expression of a polynucleotide. The expression cassette includes a promoter/enhancer, an intervening region, and a polyadenylation signal domain. Expression systems and methods of using the expression cassette and vector are also provided.
Abstract: This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other chemotherapeutic agents, as well as therapeutic methods and screening methods for identifying agents that in combination with a lymphotoxin-beta receptor agonist agent have a supra-additive effect on tumor inhibition.
Abstract: Monoclonal anti-human CD20 antigen binding antibodies containing human IgG3 constant domains are provided. These antibodies possess effector functions that render them well suited for use in therapeutic methods, especially treatments wherein inhibition of B cell function or B cell number is therapeutically desirable.
Abstract: Multivalent antibody constructs that are specific for the human lymphotoxin beta receptor, as well as their use in treating cancer and inhibiting tumor volume in a subject are disclosed.
Type:
Application
Filed:
June 17, 2005
Publication date:
May 18, 2006
Applicant:
Biogen Idec MA Inc.
Inventors:
Ellen Garber, Veronique Bailly, Jeffrey Browning
Abstract: Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide.
Type:
Grant
Filed:
November 20, 2003
Date of Patent:
May 9, 2006
Assignees:
Biogen Idec MA Inc., The General Hospital Corporation
Abstract: Nucleic acids and proteins that are overexpressed in colon or colorectal tumor tissues, and which are useful diagnostic and therapeutic targets.
Abstract: A cell adhesion inhibitor of the general formula: R3-L-L?-R1 is disclosed. An inhibitor of the present invention interacts with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. Also disclosed are methods for preparing and using such a cell adhesion inhibitor, as well as pharmaceutical compositions containing the same.
Type:
Grant
Filed:
October 3, 2003
Date of Patent:
April 25, 2006
Assignee:
Biogen Idec MA Inc.
Inventors:
Daniel Scott, Wen-Cherng Lee, Russell C. Petter, Mark Cornebise
Abstract: Compounds of Formula I and II are disclosed as antagonists of subtype A1 adenosine receptors. These compounds are useful for treatment of various diseases and disorders, including systemic hypertension, renal failure, diabetes, asthma, an edematous condition, congestive heart failure, and renal dysfunction.
Abstract: The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.
Abstract: Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing a microfluidized antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.
Type:
Application
Filed:
July 7, 2005
Publication date:
March 16, 2006
Applicant:
BIOGEN IDEC INC.
Inventors:
Syamal Raychaudhuri, William Rastetter, Amelia Black
Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
Type:
Grant
Filed:
July 24, 2003
Date of Patent:
February 21, 2006
Assignee:
Biogen Idec MA Inc.
Inventors:
Steven P. Adams, Ko-Chung Lin, Wen-Cherng Lee, Alfredo C. Castro, Craig N. Zimmerman, Charles E. Hammond, Yu-Sheng Liao